Considering that the NOTCH inhibitor has an off-target effect and is toxic if applied systemically, designing a more effective way to target CCL2/CSF1 can be a feasible immune intervention for DLBCL treatment. This evidence concerns the gene CSF1 and diffuse large B-cell lymphoma.